Dr. Victor Bustos is the Co-Founder and CEO of Refoxy Pharmaceuticals GmbH, a Cologne-based biotech company pioneering first-in-class therapies that activate the FOXO3 gene – a master regulator linked to human longevity and stress resistance.
Under his leadership, Refoxy has built an innovative drug-discovery platform to identify small-molecule FOXO3 activators, to transform cutting-edge aging research into therapies for the treatment of diverse age-related diseases, starting with Idiopathic Pulmonary Fibrosis
Previously, Dr. Bustos worked as an entrepreneur in residence at Apollo Health Ventures, where he developed the idea behind Refoxy Pharma. Dr. Bustos earned his PhD at the Max Planck Institute for Biology of Ageing in Germany and is committed to a science-driven approach – “following biology” – to extend healthy human lifespan and to bring hope in the fight against chronic, age-associated disorders.